Ann: Director Appointment, page-13

@Kingtup

They did indicate the inventory value as of December 2024: https://investorsmedia.mesoblast.com/static-files/3565f1ec-88bc-47ef-8b88-f126202305d4
see page 9, inventory line, then on page 34 is the related note about the line, which indicates the cost of production had been expensed and recognised in Jun 2024. So, they've recognised USD$24.2 million of inventory (correct me if I've got that wrong).

In the June 2024 report (the expense was USD$15.7 million, which represented a decrease of 43% (due to one-off costs, most probably related to equipment and site costs (assumption - someone can feel free to correct me on that, I'm sure theres balance sheet entries that can be read, but I'm not an accountant so don't live in these types of reports) https://investorsmedia.mesoblast.com/static-files/0bed7b26-44da-42d7-b04b-841ad4dc5acd (see the bullet point related to manufacturing on page 4).

So, I'm not sure whether an inventory cost directly relates to a salable cost, someone can add that, but it would appear that COGP is 64% of recognised invetory value. Thats not an indication of sale value.

This doctor has stated related costs on LinkedIn, but I don't know how reliable it is: https://www.linkedin.com/posts/patrickjhanley_can-mesoblasts-194k-ryoncil-treatment-generate-activity-7300961664969891840-Fm6v/
He has claimed, US$194k per infusion, with the standard course of 8 treatments, equalling US$1.55 per patient.

It's anyones guess what number of infusions is represented in the recognised inventory valuation.

Hope thats useful!